BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 10933645)

  • 1. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK; Abraham OC; Chandrasekar PH
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC; Hsieh MI; Choi PC; Wu CJ
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
    Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
    Chandrasekar PH; Cutright JL; Manavathu EK
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
    Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL; Moore CB; Denning DW
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
    Silvanose CD; Bailey TA; Di Somma A
    Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
    Espinel-Ingroff A; Rezusta A
    J Clin Microbiol; 2002 Jun; 40(6):2101-7. PubMed ID: 12037072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.